Overview of Complement Activation and Regulation
Marina Noris(Mario Negri Institute for Pharmacological Research), Giuseppe Remuzzi(Mario Negri Institute for Pharmacological Research)
Cited by 864
Related Papers
von Willebrand Factor–Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic–Uremic Syndrome
|New England Journal of Medicine|1998|1.7k
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
|New England Journal of Medicine|2013|990
Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria
|The Lancet|1999|909
Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial
|The Lancet|2005|644
Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials
|The Lancet Diabetes & Endocrinology|2019|372